A novel local anesthetic system: transcriptional transactivator peptide-decorated nanocarriers for skin delivery of ropivacaine

Chuanyu Chen
Peijun You
Department of Anesthesiology,
Shandong Jining No 1 People’s Hospital, Jining, Shandong,
People’s Republic of China

Purpose: Barrier properties of the skin and physicochemical properties of drugs are the main factors for the delivery of local anesthetic molecules. The present work evaluates the anesthetic efficacy of drug-loaded nanocarrier (NC) systems for the delivery of local anesthetic drug, ropivacaine (RVC).

Methods: In this study, transcriptional transactivator peptide (TAT)-decorated RVC-loaded NCs (TAT-RVC/NCs) were successfully fabricated. Physicochemical properties of NCs were determined in terms of particle size, zeta potential, drug encapsulation efficiency, drug-loading capacity, stability, and in vitro drug release. The skin permeation of NCs was examined using a Franz diffusion cell mounted with depilated mouse skin in vitro, and in vivo anesthetic effect was evaluated in mice.

Results: The results showed that TAT-RVC/NCs have a mean diameter of 133.2 nm and high drug-loading capacity of 81.7%. From the in vitro skin permeation results, it was observed that transdermal flux of TAT-RVC/NCs was higher than that of RVC-loaded NCs (RVC/NCs) and RVC injection. The evaluation of in vivo anesthetic effect illustrated that TAT-RVC/NCs can enhance the transdermal delivery of RVC by reducing the pain threshold in mice.

Conclusion: These results indicate that TAT-decorated NCs systems are useful for overcoming the barrier function of the skin, decreasing the dosage of RVC and enhancing the anesthetic effect. Therefore, TAT-decorated NCs can be used as an effective transdermal delivery system for local anesthesia.

Keywords: local anesthetic system, ropivacaine, transcriptional transactivator peptide, nanocarriers, skin delivery

Introduction

Ropivacaine (RVC), a congener of mepivacaine and bupivacaine, belongs to the class of long-acting amide-type local anesthetics (LAs). Based on eight clinical studies, RVC hydrochloride injection (Naropin®; Fresenius Kabi, Lake Zurich, IL, USA) has been approved by the US Food and Drug Administration (FDA) since 1996, indicating for the production of local or regional anesthesia for surgery and for acute pain management. Compared with bupivacaine and other agents in the class, RVC has the following advantages of clinical efficacy and safety: better sensory-motor differential blockade, longer duration, less central nervous system (CNS), and cardiovascular toxicities. Whereas, various clinical studies indicated that RVC was rapidly cleared from the injection site and showed short efficacy of the severity of pain (approximately 2 h postoperatively). Moreover, intravenous administration brings poor patient convenience and other toxicities such as arrhythmia. These clinical results have prompted that it was critical to the development...
of appropriate delivery systems and different administration routes that circumvent the aforementioned problem.

Drug delivery of LAs via the skin brings a lot of benefits such as delivering the local drug continuously and reducing systemic adverse reactions.\textsuperscript{11,12} Polymeric nanoparticles have been used for skin delivery.\textsuperscript{13} In one study, the effect of the inclusion of flufenamic acid in poly(lactide-co-glycolide) nanoparticles on the transport of flufenamic acid into excised human skin was investigated.\textsuperscript{14} In another study, lidocaine-loaded poly(epsilon-caprolactone)-polyethylene glycol-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles were prepared, and a transdermal lidocaine formulation, lidocaine-loaded PCL-PEG-PCL nanoparticles in F127 hydrogel (Nano-Lido Gel), was demonstrated.\textsuperscript{15} Shim et al\textsuperscript{16} evaluated the effect of hydrodynamic size of self-assembled nanoparticles on skin penetration of minoxidil in vitro and in vivo. Accordingly, polymeric materials had been selected to prepare nanocarriers (NCs) in this study.

Various studies show that transcriptional transactivator peptide (TAT) can successfully enhance the transepidermal absorption of therapeutic molecules for the local therapy.\textsuperscript{17–19} Chen et al\textsuperscript{19} reported that superoxide dismutase mediated with HIV-TAT could penetrate through stratum corneum and effectively attenuate ultraviolet B (UVB)-induced damages in human skin. Furthermore, Wang et al\textsuperscript{20} reported that TAT-conjugated and octadecyl-quaternized lysine-modified chitosan polymeric liposomes effectively enhanced skin permeation, thus achieving rapid and effective local transdermal anesthetics. More recently, Wang et al\textsuperscript{21} used TAT-modified NCs to enhance transepidermal delivery of lidocaine on the mice model and found that the system was useful for overcoming the skin barrier and delivering anesthetic through the skin.

In this study, TAT-conjugated poly(lactide-co-glycolide)-polyethylene glycol (TAT-PEG-PLGA) was synthesized. RVC was encapsulated into TAT-PEG-PLGA contained NCs (TAT-decorated, RVC-loaded NCs [TAT-RVC/NCs]), and this polymeric nanoparticle system was used to enhance the local anesthesia of RVC. TAT-RVC/NCs were fabricated and characterized for their size, loading efficiency, stability, and drug release. These NCs were subsequently assessed for in vitro skin permeation and/or in vivo anesthetic/analgesic effects in animal models.

**Materials and methods**

**Materials**

TAT peptide with terminal cysteine (Cys-AYGRKRR QRRR) was obtained from Chinese Peptide Co., Ltd. (Hangzhou, China). Poly(lactide-co-glycolide)-polyethylene glycol-maleimide (PLGA-PEG-Mal) was purchased from Xi’an Ruixi Biological Technology Co., Ltd (Xi’an, China). RVC hydrochloride monohydrate (≥ 98% (high-performance liquid chromatography [HPLC])) was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Carbopol 940 (CP; molecular weight [MW] 1,000,000) was provided by Shanghai Renmin Pharmaceutical Factory (Shanghai, China). RVC hydrochloride injection (Naropin) was provided by AstraZeneca plc (London, UK). All other chemicals and reagents were of analytical grade or HPLC grade.

**Animals**

Sprague Dawley (SD) rats (350–400 g, 10–12 weeks old) were purchased from the Medical Animal Test Center of Shandong University (Jinan, China) and used for experiments after 1 week of acclimatization. Rats were fed with standard diet, allowed water ad libitum, and housed in an air-conditioned room (22°C–24°C, 12 h light cycle). Animal experiments were conducted according to the Guide for the Care and Use of Laboratory Animals established by Shandong University. Ethics approval was received from the Medical Ethics Committee of Shandong Jining No 1 People’s Hospital (reference number: SDJNPH20161118002).

**Synthesis of TAT-PEG-PLGA**

TAT-PEG-PLGA was synthesized using the method described by Koren et al.\textsuperscript{22} Briefly, 300 mg PLGA-PEG-Mal, 100 mg Cys-TAT, and 1 mL triethylamine were reacted in 20 mL chloroform at room temperature with gentle stirring for 24 h at room temperature. The solvent was then dialyzed against deminized water using a membrane with MW cutoff (MWCO) of 13 kDa for 24 h. The product was then lyophilized for use. The reaction progress was monitored by thin-layer chromatography (TLC).\textsuperscript{23} TLC confirmed the formation of TAT-PEG-PLGA as the spot of PLGA-PEG-Mal disappeared after the reaction.

**Pretreatment of stabilizer solution**

CP was first dispersed in distilled water overnight to swell it. Then, it was neutralized by adding the required amount of 1 mol/L of NaOH to adjust the pH to 7.\textsuperscript{24} Afterward, the CP solution was diluted with distilled water into a concentration of 0.02% (w/v).

**Preparation of TAT-RVC/NCs**

Prior to the preparation of NCs, RVC hydrochloride monohydrate was stirred twice with the molar amount of triethylamine in dimethyl sulfoxide (DMSO) for 12 h to
obtain lipophilic RVC base. TAT-RVC/NCs (Figure 1) were prepared by a solvent displacement technique. Briefly, 200 mg of TAT-PEG-PLGA and 50 mg of RVC were accurately weighed and dissolved in 5 mL acetone. The organic phase was added dropwise into a desired aqueous stabilizer of 0.02% CP being stirred at 400 rpm by a laboratory magnetic stirrer at room temperature for 8 h to completely evaporate the organic solvent. Then, TAT-RVC/NCs were harvested by ultracentrifugation (15,000 rpm, 4°C, 15 min) and resuspended in Milli-Q water. Then, the supernatant was collected and washed using Milli-Q water twice, resuspended in phosphate-buffered saline (PBS; pH 7.4), filtered through a membrane (pore size of 0.45 µm), and lyophilized using 0.5% (w/v) mannitol as a cryoprotectant.

Non-TAT-decorated RVC-loaded NCs (RVC/NCs) were prepared by the same method using PLGA-PEG instead of TAT-PEG-PLGA. Blank NCs were prepared by the same method without adding RVC.

**Drug encapsulation efficiency (EE) and drug-loading (DL) capacity**

Drug EE and DL capacity were evaluated by quantifying the amount of entrapped RVC in the NCs. To separate RVC-loaded NCs from free RVC, Sephadex G-50 mini column centrifugation technique (size exclusion chromatography, SEC) was utilized. SEC is a chromatographic method in which molecules in solution are separated by their size, and in some cases the MW. It is generally applied to large molecules or macromolecular complexes such as proteins and polymers. Typically, when an aqueous solution is used to transport the sample through the column, the technique is known as gel-filtration chromatography, versus the name gel permeation chromatography, which is used when an organic solvent is used as a mobile phase. Briefly, 0.5 mL of TAT-RVC/NCs or RVC/NCs was placed onto a Sephadex G-50 mini column. The elution was conducted by adding 0.5 mL of distilled water and then centrifuging for 1 min at 500 rpm. Finally, the eluate was collected and mixed with methanol to break down the structure of NCs. The amount of entrapped RVC was detected by HPLC. The EE and DL of RVC-loaded NCs were calculated as follows:

\[
\text{DL} (\%) = \frac{\text{Amount of RVC loaded in NCs}}{\text{All materials in the system}} \times 100
\]

\[
\text{EE} (\%) = \frac{\text{Amount of RVC loaded in NCs}}{\text{Amount of RVC in the system}} \times 100
\]

**Mean diameter and zeta potential**

The measurements of mean diameter, polydispersity indices (PDIs), and zeta potential were performed by dynamic light scattering (photon correlation spectroscopy, PCS) using a ZetaSizer Nano ZS90 analyzer (Malvern Instruments, Malvern, UK).

**Stability of TAT-RVC/NCs**

Stability of TAT-RVC/NCs, RVC/NCs, and NCs was evaluated by measuring mean diameter, PDI, zeta potential, and EE for 90 days. The suspensions were stored in amber flasks at ambient temperature. The results were calculated, and the analyses were performed at the predetermined time intervals (0, 15, 30, 60, and 90 days).

**In vitro drug release**

In vitro release behaviors of RVC from TAT-RVC/NCs, RVC/NCs, and RVC hydrochloride injection (RVC/IJ) in PBS at 37°C were evaluated for 48 h using a dialysis method. Briefly, 1 mL of solution was placed into a cellulose membrane dialysis tube (MWCO =8,000–12,000), suspended in 20 mL of PBS (pH 7.4), and gently shaken for 48 h at 37°C in a water bath at 100 rpm. At predetermined
time points, 1 mL of releasing medium was withdrawn and refilled with the same amount of the fresh medium, and the released RVC was detected by HPLC.

**In vitro skin permeation study**

In vitro skin penetration experiments of TAT-RVC/NCs, RVC/NCs, and RVC/IJ were performed on Franz diffusion cells as follows:29,30 SD rats were sacrificed, and the fur on the abdominal area of the rats was carefully removed. The skin from the abdominal surface was excised, and the adherent fat and subcutaneous tissue was removed. The receptor compartment was filled with 10 mM phosphate buffer (pH 7.4), and the full thickness of skin was mounted on the diffusion cell with stratum corneum facing up and dermis being in contact with the receptor medium. The diffusion cells with the skin were maintained at 37°C±0.5°C under non-occlusive conditions. The skin samples were mounted on Franz diffusion cell with a surface area of 0.66 cm² and a receptor volume of 5 mL. TAT-RVC/NCs, RVC/NCs, and RVC/IJ (containing 10 mg of RVC) were applied on the donor compartment side of the skin, separately. Then, 0.5 mL of receptor medium was withdrawn at time intervals of 0, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 h and was replaced by the same volume of fresh buffer to maintain the sink condition. The amount of RVC in the receptor fluid samples was assayed by HPLC. The flux of drug from each formulation was calculated.31 The cumulative drug permeation (Q) was calculated from the following equation:

\[ Q_i = V_r C_i + \sum_{j=0}^{i-1} V_r C_j \]

where \( V_r \) and \( V_i \) are the volumes of the receptor fluid; \( C_i \) is the drug concentration of the receptor fluid; and \( C_j \) is the drug concentration of the sample of the "i" value. Data were reported in the cumulative drug permeation per unit of skin surface area, \( Q/S \) (\( S = 0.66 \) cm²). The steady-state fluxes (\( J_{ss} \)) were calculated by linear regression interpolation of the experimental data at steady state (\( \Delta T \)) as shown in the following equation:

\[ J_{ss} = \frac{Q_i}{(\Delta T \times S)} \]

**In vivo pharmacokinetics evaluation**

Important pharmacokinetics profiles of TAT-RVC/NCs, RVC/NCs, and RVC/IJ groups were evaluated.32 Rats were randomly divided into three groups (n=6 each) as follows: 1) TAT-RVC/NCs group; 2) RVC/NCs group; and 3) RVC/IJ group. The fur on the abdominal area was carefully removed. The next day, TAT-RVC/NCs and RVC/NCs were applied onto the skin, and RVC/IJ was applied by subcutaneous injection (1 mg RVC per rat). After 5, 10, 15, 20, 30, 45, 60, 75, and 90 min, the skin tissue was collected and homogenized with 10 times the volume of PBS. The obtained homogenate was centrifuged at 10,000 rpm for 10 min, and the supernate was collected. The amount of RVC in the supernate was detected by HPLC as mentioned earlier.

**In vivo anesthetic effect evaluation**

Tail-flick (TF) test was applied for evaluating the in vivo anesthetic effect of TAT-RVC/NCs, RVC/NCs, and RVC/IJ.33 Rats were randomly divided into four groups (n=6 each) as follows: 1) TAT-RVC/NCs group; 2) RVC/NCs group; 3) RVC/IJ group; 4) 0.9% saline group. A noxious heat stimulus was applied via a focused, radiant heat source to the dorsal surface of the tail. TF test started 5 min after the local application of TAT-RVC/NCs, RVC/NCs, RVC/IJ, or 0.9% saline. TF latency was converted to represent the maximum possible effect (MPE) according to the following formula:

\[ \text{MPE} (\%) = \left( \frac{(\text{Test latency}) - (\text{Baseline latency})}{(\text{Cutoff time}) - (\text{Baseline latency})} \right) \times 100. \]

The baseline latency was calculated as the mean of three different measurements taken at 15 min intervals. Baseline latencies were typically ranged from 2.5 to 3.0 s. A maximum cutoff time of 10 s was set to avoid tissue damage in analgesic animals.

**Statistical analysis**

All data are expressed as mean ± standard deviation. Statistical analyses were performed using Student’s t-test. Differences were considered significant when the P-value was <0.05.

**Results**

**Preparation and characterization of TAT-RVC/NCs**

TAT-RVC/NCs were characterized by EE, DL, mean diameter, and zeta potential (Table 1). The EE was 81.7%±3.1% and 82.4%±2.8% and the DL was 8.2%±0.8% and 9.3%±0.9% for the TAT-RVC/NCs and RVC/NCs, respectively.

Mean diameter of TAT-RVC/NCs, RVC/NCs, and NCs was around 130 nm, with narrow PDIs (below 0.2).
The average diameter of TAT-RVC/NCs obtained in this study was 130 nm. The zeta potential of TAT-RVC/NCs was $-19.1$ mV.

**Stability of the TAT-RVC/NCs**

The stabilities of TAT-RVC/NCs, RVC/NCs, and NCs were evaluated over a period of 90 days of storage in amber flasks at ambient temperature. For both kinds of NCs, the average particle diameter remained almost constant throughout the period (Figure 2A). There were no significant changes with time of the PDIs of all the formulations tested (Figure 2B). For both formulations, the zeta potential was negative and showed no major changes during the 90 days of storage (Figure 2C). The RVC EE of TAT-RVC/NCs and RVC/NCs

### Table 1 Characterization of TAT-RVC/NCs, RVC/NCs, and NCs

<table>
<thead>
<tr>
<th>Formulation</th>
<th>EE</th>
<th>DL</th>
<th>Mean diameter</th>
<th>PDI</th>
<th>Zeta potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAT-RVC/NCs</td>
<td>81.7±3.1</td>
<td>8.2±0.8</td>
<td>133.2±4.6</td>
<td>0.193±0.021</td>
<td>−19.1±1.3</td>
</tr>
<tr>
<td>RVC/NCs</td>
<td>82.4±2.8</td>
<td>9.3±0.9</td>
<td>134.1±3.7</td>
<td>0.127±0.018</td>
<td>−27.8±2.4</td>
</tr>
<tr>
<td>NCs</td>
<td>N/A</td>
<td>N/A</td>
<td>128.9±3.1</td>
<td>0.091±0.009</td>
<td>−26.3±1.7</td>
</tr>
</tbody>
</table>

**Note:** Data represent mean ± SD (n=3).

**Abbreviations:** DL, drug loading; EE, encapsulation efficiency; NCs, nanocarriers; PDI, polydispersity index; RVC, ropivacaine; SD, standard deviation; TAT, transcriptional transactivator peptide; RVC/NCs, RVC-loaded NCs; TAT-RVC/NCs, TAT-decorated RVC-loaded NCs; N/A, not available.

![Figure 2](https://www.dovepress.com/)

**Figure 2** Stabilities of TAT-RVC/NCs, RVC/NCs, and NCs in terms of mean particle diameter (A), PDI (B), zeta potential (C), and EE (D).

**Note:** Data represent mean ± SD (n=3).

**Abbreviations:** EE, encapsulation efficiency; NCs, nanocarriers; PDI, polydispersity index; RVC, ropivacaine; SD, standard deviation; TAT, transcriptional transactivator peptide; RVC/NCs, RVC-loaded NCs; TAT-RVC/NCs, TAT-decorated RVC-loaded NCs.
also remained stable at all the time points tested in the research (Figure 2D).

**In vitro drug release**

In vitro drug release profiles of TAT-RVC/NCs, RVC/NCs, and RVC/IJ are shown in Figure 3. Significant differences in the release patterns were observed between drug injection and drug-loaded NCs ($P<0.05$). The drug-loaded NCs led to a slower release rate of RVC compared with injection. It was clear that encapsulation into polymeric NCs exhibited an obvious sustained release.

**In vitro skin permeation**

In vitro permeation behaviors of TAT-RVC/NCs, RVC/NCs, and RVC/IJ were calculated (Figure 4A), and the $J_{ss}$ were summarized (Figure 4B). The $J_{ss}$ of TAT-RVC/NCs, RVC/NCs, and RVC/IJ were 19.7±1.1, 14.2±1.2, and 8.6±0.8, respectively. The permeation of RVC loaded in NCs was much more sufficient than RVC injection ($P<0.05$). The highest skin permeation was provided by TAT-RVC/NCs. The $J_{ss}$ of TAT-RVC/NCs was significantly higher than that of RVC/NCs ($P<0.05$).

**In vivo pharmacokinetics evaluation**

Pharmacokinetic profiles of TAT-RVC/NCs, RVC/NCs, and RVC/IJ after administration to rat skin are shown in Figure 5. RVC/IJ showed the highest tissue level of itself (98 μg/g weight) at 10 min after injected to the skin. TAT-RVC/NCs and RVC/NCs showed sustained-release behavior and the highest skin tissue RVC levels were reached at 4 h after application. TAT-RVC/NCs showed maximum tissue RVC level, higher than that of RVC/NCs and RVC/IJ.

**In vivo anesthetic effect**

In vivo anesthetic effect of TAT-RVC/NCs, RVC/NCs, and RVC/IJ was reviewed by TF test. TAT-RVC/NCs, RVC/NCs, and RVC/IJ increased the TF latency dramatically (Figure 6). There were no significant differences in baseline TF latency among all the groups tested. The time MPE in the saline group showed no obvious change during the experiment. RVC-loaded NCs showed fast and effective, and also long-lasting effect; on the contrary, the RVC/IJ showed a fast but short-lasting anesthetic effect. TAT-RVC/NCs induced a remarkable anesthetic effect, persisting until 45 min after the administration.

**Discussion**

Polymeric nanoparticles for the delivery of LAs via the skin bring a lot of advantages such as delivering the local drug continuously and reducing systemic adverse reactions. TAT can successfully enhance the transepidermal absorption of therapeutic molecules for the local therapy. In this study, TAT-decorated RVC was encapsulated and NC system was prepared and used to enhance the local anesthesia of RVC.

Table 1 summarizes the EE, DL, mean diameter, and zeta potential of NCs. Quantification of the amount of drug encapsulated in the systems could consider the RVC EE and DL differences between the TAT-decorated TAT-RVC/NCs and the non-decorated RVC/NCs. The EE and DL for the TAT-RVC/NCs and RVC/NCs had no obvious difference ($P>0.05$), suggesting that the decoration of TAT did not affect the drug encapsulation. The NCs prepared were relatively uniform and homogenous, due to narrow PDIs (below 0.2) were found in TAT-RVC/NCs, RVC/NCs, and NCs. Size was critical to topical drug delivery systems, since it was reported that vesicles smaller than 300 nm were able to deliver the drug into deeper layers of the skin. The average diameter of TAT-RVC/NCs obtained in this study was 130 nm; this may be the evidence that the formulation had potential for skin delivery of drugs. The stability of the NCs can also be influenced by the charge of the system. Since aggregation could be avoided by electrostatic repulsion between vesicles, higher zeta potential means better long-term stability. The zeta potential of TAT-RVC/NCs was ~19.1 mV, which may forecast a fine stability for the formulation.

![Figure 3](https://www.dovepress.com/...)
A novel local anesthetic system

Figure 4 In vitro permeation behaviors (A) and the steady-state fluxes (B) of TAT-RVC/NCs, RVC/NCs, and RVC/IJ.

Note: Data represent mean ± SD (n=3).

Abbreviations: NCs, nanocarriers; RVC, ropivacaine; SD, standard deviation; TAT, transcriptional transactivator peptide; RVC/NCs, RVC-loaded NCs; TAT-RVC/NCs, TAT-decorated RVC-loaded NCs; RVC/IJ, RVC hydrochloride injection.

The stabilities of TAT-RVC/NCs, RVC/NCs, and NCs were evaluated over a period of 90 days in terms of the mean particle diameter, PDI, zeta potential, and EE. For both kinds of NCs, no aggregate was found for the average particle diameter remained almost constant throughout the period. PDIs less than 0.2 are normally used to indicate the existence of a narrow particle size range. Large fluctuations with time could indicate aggregate formation, hence increasing the nanoparticle size range.

There were no significant changes with time of the PDIs of all the formulations tested, showing the stability of the NCs. The value of the zeta potential also provides an indication of the stability of NCs in suspension.

For both formulations, the zeta potential was negative and showed no major changes during the 90 days of storage. The RVC EE of TAT-RVC/NCs and RVC/NCs also remained stable.
stable at all the time points tested in the research, indicating that the NCs were stable within 3 months.

In vitro RVC release profiles of TAT-RVC/NCs, RVC/NCs, and RVC/IJ illustrated that the RVC released from NCs in sustained manners. The sustained-release behavior is an important prerequisite for successful drug delivery. This phenomenon could be explained by the entrapment of the drugs by the polymer which can slow down the release of the drugs. Complete releases of drug in TAT-RVC/NCs and RVC/NCs were achieved at 48 h. This could contribute to the use of PLGA-PEG which incorporated RVC and let it release in a more sustained rate.

**Conclusion**

It can be concluded that the skin permeation efficiency of RVC from TAT-decorated NCs was increased. This could be explained by the fact that nano-sized NCs have the ability to permeate through the skin surface. In vitro and in vivo studies showed that TAT-RVC/NCs more effectively promoted skin permeation capacity and anesthetic effect. Therefore, TAT-decorated NCs can be used as an effective transdermal delivery system for local anesthesia.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**